This session explores how hybrid AI infrastructure is transforming drug discovery by integrating on-premises, private cloud, and public cloud resources for optimal data control, computational power, scalability, and security. Attendees will learn how pharmaceutical organizations use cutting-edge AI and machine learning tools for target identification and molecular design, while maintaining compliance with strict regulatory standards. The presentation will cover the architecture and core components of hybrid infrastructure, including high-performance computing, data management, MLOps, and compliance frameworks. Key benefits such as accelerated R&D, cost reduction, improved collaboration, and flexible scalability will be discussed, alongside real-world case studies. The session will also address challenges like data integration, interoperability, regulatory complexity, and AI interpretability, offering practical strategies to overcome these obstacles.
Alex Madama
Alex Madama is a Distinguished Technologist at Hewlett Packard Enterprise, specializing in strategic technology integration for life sciences organizations, including healthcare, pharmaceutical, biotech, and medical device companies. He leads initiatives combining high-performance computing, Hybrid Cloud, IoT, big data, and AI to advance drug discovery, pharmaceutical R&D, and biologics manufacturing, aiming to optimize patient outcomes and reduce costs. Before re-joining HPE, Alex served as Vice President of Product at UnitedHealth Group R&D, where he drove innovation in healthcare research and development. He holds a bachelor’s degree in life science and a Doctor of Osteopathic Medicine from New York Institute of Technology, with additional clinical training at Good Samaritan Hospital Medical Center, and lectures as an Adjunct Professor of Health Information Technology at Hofstra University. Previously, Alex founded Onyx CCS and held leadership roles at Nook.com, Barnes & Noble, AIG, Cravath Swaine & Moore, and as founder of seekPhysician.com.